Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County COVID Drug Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Coronavirus 19 (COVID-19) Anti-Stockpiling Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs quantity limits and prior authorization requirements for selected medications used for COVID-19, malaria prophylaxis, rheumatoid arthritis, lupus, or HIV-1 infection. It applies to providers requesting coverage under Ventura County Health Care Plan.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCoronavirus 19 (COVID-19) Anti-Stockpiling Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 20, 2020
    Next Review DateN/A
    Key ActionObtain prior authorization for medication beyond the supply provided for one COVID-19 episode in a 365-day period.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Drug formulations with 365-day quantity limits
    365 daysStandard COVID-19 supply period
    1 episodeCOVID-19 episode supply without additional authorization
    90/30 daysMaximum Plaquenil quantity for chronic rheumatologic treatment

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    56 tablets
    Additional COVID-19 override for chloroquine 250 mg and Kaletra 200/50 mg
    160 mLAdditional COVID-19 override for Kaletra oral solution

    Coverage Criteria

    Additional COVID-19 Episode

    Coverage for an additional Coronavirus 2019 (COVID-19) episode within a 365-day period may be approved when ANY of the following formulation-specific limits applies:

    ONE of

    • Chloroquine 250 mg tablets are requested for an additional COVID-19 episode within a 365-day period.One-time override: 56 tablets
    • Chloroquine 500 mg tablets are requested for an additional COVID-19 episode within a 365-day period.One-time override: 28 tablets
    • Plaquenil 200 mg tablets are requested for an additional COVID-19 episode within a 365-day period.One-time override: 28 tablets
    • Kaletra 200/50 mg tablets are requested for an additional COVID-19 episode within a 365-day period.One-time override: 56 tablets
    • Kaletra 100/25 mg tablets are requested for an additional COVID-19 episode within a 365-day period.One-time override: 112 tablets
    • Kaletra 80/20 mg per ml oral solution is requested for an additional COVID-19 episode within a 365-day period.One-time override: 160 ml (1 bottle)

    Malaria Prophylaxis

    Malaria prophylaxis therapy may be approved when the requested quantity supports the applicable formulation-specific regimen:

    ONE of

    • Chloroquine 250 mg tablets are requested for malaria prophylaxis: 500 mg (2 tablets) weekly for 2 weeks before entering a malaria endemic area, during the stay in the endemic area, and for 8 weeks after return.

      Quantity must be sufficient for the full prophylaxis period.

    • Chloroquine 500 mg tablets are requested for malaria prophylaxis: 500 mg (1 tablet) weekly for 2 weeks before entering a malaria endemic area, during the stay in the endemic area, and for 8 weeks after return.

      Quantity must be sufficient for the full prophylaxis period.

    • Plaquenil 200 mg tablets are requested for malaria prophylaxis: 400 mg (2 tablets) weekly for 2 weeks before entering a malaria endemic area, during the stay in the endemic area, and for 4 weeks after return.

      Quantity must be sufficient for the full prophylaxis period.

    Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Lupus Nephritis

    Coverage may be approved when the patient has a chronic rheumatologic indication and the requested quantity is within the stated limit:

    ALL of the following

    • ONE of

      • Patient has rheumatoid arthritis (RA).
      • Patient has systemic lupus erythematosus (SLE).
      • Patient has lupus nephritis.
    • Plaquenil 200 mg tablets are requested for treatment of the qualifying condition.Up to 90 tablets per 30 days for 12 months

    HIV-1 Infection

    Kaletra may be approved for treatment of HIV-1 infection when the requested amount is approved for the applicable formulation:

    ONE of

    • Kaletra 200/50 mg tablets are being used for the treatment of HIV-1 infection.

      Approve the requested amount.

    • Kaletra 100/25 mg tablets are being used for the treatment of HIV-1 infection.

      Approve the requested amount.

    • Kaletra 80/20 mg per ml oral solution is being used for the treatment of HIV-1 infection.

      Approve the requested amount.

    Medication Formulations and Standard Limits

    Chloroquine 250 mg tablets
    Medication allowed per 365-day period56 tablets
    Chloroquine 500 mg tablets
    Medication allowed per 365-day period28 tablets
    Plaquenil (hydroxychloroquine) 200 mg tablets
    Medication allowed per 365-day period28 tablets
    Kaletra 200 mg/50 mg tablets
    Medication allowed per 365-day period

    Prior Authorization Requirements

    Prior Authorization

    Request prior authorization for additional medication

    Prior authorization is required for coverage of medication beyond the supply provided for one episode of Coronavirus 2019 (COVID-19) in a 365-day period.

    Policy Background

    This policy addresses chloroquine tablets, hydroxychloroquine tablets (Plaquenil), and lopinavir/ritonavir tablets and oral solution (Kaletra). These medications may be used for conditions including parasitic diseases, rheumatoid arthritis, systemic lupus erythematosus, and HIV-1 infection, and are also addressed in the context of Coronavirus 2019 (COVID-19) treatment. The policy limits dispensing to help prevent stockpiling, misuse, and overuse while providing medication for one COVID-19 episode in a 365-day period.

    Plaquenil Continuation

    Plaquenil Continuation for RA, SLE, or Lupus Nephritis

    Coverage may continue for chronic rheumatologic treatment when both conditions below are met.

    Continuation Plaquenil therapy

    • The patient has rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), or lupus nephritis.
    • The patient is receiving Plaquenil 200 mg tablets.Up to 90 tablets per 30 days for 12 months

    365-Day Quantity Limits

    Chloroquine 250 mg tablets
    Quantity limit56 tablets
    Chloroquine 500 mg tablets
    Quantity limit28 tablets
    Plaquenil (hydroxychloroquine) 200 mg tablets
    Quantity limit28 tablets
    Kaletra 200 mg/50 mg tablets
    Quantity limit
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCoronavirus 19 (COVID-19) Anti-Stockpiling Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMar 20, 2020
    Next Review DateN/A
    Key ActionObtain prior authorization for medication beyond the supply provided for one COVID-19 episode in a 365-day period.
    SourceLink
    On This Page
    Coverage CriteriaMedication Formulations and Standard LimitsPrior Authorization RequirementsPolicy BackgroundPlaquenil Continuation365-Day Quantity Limits
    56 tablets
    Kaletra 100 mg/25 mg tablets
    Medication allowed per 365-day period112 tablets
    Kaletra 80 mg/20 mg/mL oral solution
    Medication allowed per 365-day period160 mL (1 bottle)
    56 tablets
    Kaletra 100 mg/25 mg tablets
    Quantity limit112 tablets
    Kaletra 80 mg/20 mg/mL oral solution
    Quantity limit160 mL (1 bottle)